Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 4/20 | 0.32 |
| ▸ | ELANE | P08246 | 3/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.31 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.31 |
| ▸ | USP8 | P40818 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31748052 | 0.83 | RPS6KA3 (0.37) | CYP1A2CYP2A6ALDH1A1CA1CA2 | |
| SCHEMBL17427808 | 0.76 | TDP2 (0.33) | CYP1A2 | |
| SCHEMBL30417607 | 0.74 | CYP1A2 (0.33) | CYP1A2CYP2A6ALDH1A1CA1CA2 | |
| SCHEMBL3227957 | 0.74 | TDP2 (0.35) | — | |
| SCHEMBL7724583 | 0.74 | DBH (0.37) | CYP1A2ALDH1A1CA1CA2CA7 | |
| SCHEMBL25418829 | 0.74 | CYP3A4 (0.33) | ALDH1A1TSHRPARP1ELANETDP1 | |
| SCHEMBL1515006 | 0.74 | CA12 (0.31) | CA9PARP1 | |
| SCHEMBL11218287 | 0.74 | TSHR (0.38) | CYP1A2CYP2A6ALDH1A1CA9TSHR | |
| SCHEMBL640435 | 0.74 | CYP3A4 (0.33) | ALDH1A1TSHRPARP1ELANETDP1 | |
| SCHEMBL11135354 | 0.74 | CA1 (0.39) | CYP2A6ALDH1A1CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104513494-A | Preparation method for pigment orange 64 with high color intensity | SHANGYU SHUNLIAN CHEMICAL CO LTD | 2015-04-15 | — | — | CN | claimed |
| US-4122158-A | FOR TREATMENT OF BURNS; BIODEGRADABLE HYDROPHOBIC POLYMER; SUSTAINED RELEASE | ALZA CORPORATION (US) | 1978-10-24 | — | — | US | claimed |
| US-20250388587-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2025-12-25 | — | — | US | disclosed |
| US-20250059221-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-20 | — | — | US | disclosed |
| US-20240417388-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-12-19 | — | — | US | disclosed |
| US-20240400570-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2024-12-05 | — | — | US | disclosed |
| US-12077555-B2 | STAT degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-12065442-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | CULLGEN (SHANGHAI), INC. (CN) | 2024-08-20 | — | — | US | disclosed |
| US-11969472-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | CULLGEN (SHANGHAI), INC. (CN) | 2024-04-30 | — | — | US | disclosed |
| EP-4334307-A1 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-4287069-A | BY MIXING SLUDGE WITH RESIDUES FORMED BY REACTING TOLUENE DIISOCYANATE WITH OTHER REACTIVE COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 1981-09-01 | — | — | US | disclosed |
| EP-0027943-A1 | Working-up process for cross-linked isocyanate-distillation residues containing urea groups, and the use of the products thus obtained as starting material in the production of plastics | BAYER AG (DE) | 1981-05-06 | — | — | EP | disclosed |
| US-4251638-A | CONTAINING A REACTIVE FILLER WHICH IS DISTILLATION RESIDUE OF PRODUCTION OF TOLUENE DIISOCYANATE ISOMERS | BAYER AKTIENGESELLSCHAFT (DE) | 1981-02-17 | — | — | US | disclosed |
| US-4251401-A | FOR PRODUCTION OF POLYURETHANES | BAYER AKTIENGESELLSCHAFT (DE) | 1981-02-17 | — | — | US | disclosed |
| EP-0011702-A1 | TDI destillation residues dispersed in polyols and their use in a process for preparing polyurethane plastics | BAYER AG (DE) | 1980-06-11 | — | — | EP | disclosed |
| EP-0010675-A2 | Working-up process of toluylen diisocyanate-distillation residues and use of the products thus obtained as mouldable material or as active fillers, in particular in the production of panels and shaped articles | BAYER AG (DE) | 1980-05-14 | — | — | EP | disclosed |
| EP-0010687-A1 | Process for the production of polyurethanes from tuluylendiisocyanate residues and their use for preparing panels and moulded articles | BAYER AG (DE) | 1980-05-14 | — | — | EP | disclosed |
| US-4024125-A | Dis-azo pigments deriving from bis-diazotized diamino-2-phenyl-benzazolones | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-05-17 | — | — | US | disclosed |
| US-3987075-A | ALKYL BENZENE SOLVENT | OLIN CORPORATION (US) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11969472-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | MUSK, ERBB2, NTRK1 | CYP1A2 4437/4885CYP2A6 4083/4885ALDH1A1 4113/4885 |
| US-12077555-B2 | STAT degraders and uses thereof | STAT4, STAT1, STAT3 | CYP1A2 486/4885CYP2A6 506/4885ALDH1A1 2465/4885 |
| US-20250388587-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | ERBB2, MUSK, ERBB3 | CYP1A2 4346/4885CYP2A6 2336/4885ALDH1A1 4483/4885 |
| US-20250059221-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | CYP1A2 486/4885CYP2A6 506/4885ALDH1A1 2465/4885 |
| US-20240400570-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | CYP1A2 4437/4885CYP2A6 4083/4885ALDH1A1 4113/4885 |
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | CYP1A2 486/4885CYP2A6 506/4885ALDH1A1 2465/4885 |
| US-20240417388-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | BCL6, BCL6B, BCL3 | CYP1A2 2414/4885CYP2A6 1150/4885ALDH1A1 1654/4885 |
| US-12065442-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | MUSK, NTRK1, ERBB2 | CYP1A2 4053/4885CYP2A6 3652/4885ALDH1A1 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.